IBS (IBS) — price, market cap and strength versus Bitcoin
Bottom line
IBS trades at $0.0007 with a market capitalisation of $26.5M (rank 700). Over 90 days it is -20.2% against Bitcoin and sits below its 200-day average. DeFi as a theme is -21.1% against Bitcoin over 13 weeks. Price readings run through 2026-09-11.
Price
$0.0007
as of 2026-09-11
Market cap
$26.5M
snapshot 2026-07-04
RS vs Bitcoin · 90d
-20%
as of 2026-09-11
30-day median volume
$146.0K
as of 2026-09-11
01 · the tape, against its benchmark
How has IBS moved against Bitcoin?
IBS is -12.4% over one year, -0.4% over 90 days and -0.6% over 30 days. Annualised 30-day volatility is 6%. Its deepest fall from a high inside the last 90 days is 2%. It trades below its 200-day average, which is falling.
IBS · rebasedBitcoinDeFi · equal weight
All three lines rebased to 100 at the first week each has data. Bitcoin is the opportunity-cost benchmark for crypto risk; the theme line is its equal-weight index of current rated members.
02 · returns, volatility and drawdown
What do IBS's returns and risk look like?
7 days+0.7%
30 days-0.6%
90 days-0.4%
180 days-4.0%
1 year-12%
30-day volatility6% annualised
Deepest 90-day fall2%
200-day average$0.0007 · below · falling
50-day average$0.0007
03 · what the protocol actually earns
Does IBS generate fees or revenue?
No protocol fee, revenue, TVL, user, DEX-volume or transaction series is published for IBS, so this page shows none rather than inventing one. That is the normal case in crypto: fewer than one coin in seven has any of it.
No protocol economics are published for IBS: No protocol fee, revenue, TVL, user, DEX-volume or transaction series is published for IBS, so this page shows none rather than inventing one. That is the normal case in crypto: fewer than one coin in seven has any of it.
04 · exact additive research priority
What does the evidence say about IBS?
IBS scores 37.4 out of 100 inside DeFi, ranked 24 of 30 rated coins on 50% evidence. The four displayed point contributions add exactly to the total; missing evidence pulls only the affected factor toward neutral and lowers its stated coverage. It ranks research attention within one theme, never portfolio action, and it is not comparable across themes.
IBS · IBS
37.4/100 · Illiquid · research only · 50% evidence · rank 24 of 30 rated DeFi coins
Exact sum: 5.5 + 15.0 + 10.0 + 6.9 = 37.4
Decision use: Treat this as a tape-led lead. Require native activity confirmation before upgrading research priority.
This weakens if: The read weakens if 90-day RS versus BTC falls below zero with two weekly closes below the 200-DMA, or native activity contracts for two complete calendar quarters.
No valuation section exists on this page, for any coin. There is no company-style P/E or PEG for a token, and historical market capitalisation is not held at all — only a dated current snapshot — so no ten-year valuation band can be built honestly. Where a protocol publishes fees or revenue, the yield against that dated snapshot is shown above instead.
05 · the theme it competes in
How does IBS compare with other DeFi coins?
IBS is one of 46 DeFi coins here, 30 of which carry enough evidence to be rated and ranked. IBS ranks 24 of those 30 on 50% evidence. The table below is the theme's own scorecard, in its own order, with this coin marked.
The DeFi scorecard in its own order, with this coin marked. Scores are within-theme and are not comparable with coins in another theme. See the full DeFi page.
Methodology · boundaries make the answer useful
What can make this page misleading?
This page names 5 ways its own evidence about IBS can mislead, all listed below. The largest is that crypto network activity is not company earnings: protocol revenue does not automatically accrue to token holders. Price runs through 2026-09-11; market capitalisation is a separate snapshot dated 2026-07-04.
Crypto network activity is not company earnings. Protocol revenue does not automatically accrue to token holders.
Market capitalisation is a dated snapshot, not a point-in-time historical supply series, so yields computed against it inherit that lag.
No valuation band exists for any coin: historical market capitalisation is not held at all.
Funding rates, open interest, liquidations, exchange flows, unlock schedules and developer activity are not held and are not inferred.
The research score is relative to this coin's own theme only. It is not comparable across themes and is not an entry signal.
Price and technicalsThrough 2026-09-11, from exchange closes; moving averages are computed, never scraped.
Protocol activityNone published for this token.
Market capSnapshot dated 2026-07-04; no historical supply series is implied.
Decision useResearch priority within one theme. Not entry, exit, sizing or leverage instructions.
Questions the page should answer directly
Crypto analysis FAQs
These 6 answers cover the questions this page can settle from data it holds — what the category is, how the score is built, what the coverage gaps are, and what would change the read. Every answer below is also present in the page’s FAQ schema and in its plain-text rendition. None of them is a recommendation.
What is IBS (IBS)?
IBS is a DeFi cryptocurrency tracked here by price, market capitalisation and strength against Bitcoin, with no protocol activity data published for it. It is one of 46 DeFi coins on this site. Readings are as of 2026-09-11.
What is the market cap of IBS?
IBS's market capitalisation is $26.5M, ranking it 700 in the top-1,000 crypto universe. That figure is a dated snapshot from 2026-07-04, refreshed separately from the daily price series, so it can lag the price shown above.
Is IBS beating Bitcoin?
IBS is -20.2% against Bitcoin over 90 days, and its own theme, DeFi, is -21.1% over 13 weeks. It trades below its 200-day average as of 2026-09-11.
Does IBS have a P/E ratio?
No. There is no company-style P/E or PEG for a crypto token, and no valuation band is shown on this page because the data to build one honestly does not exist: historical market capitalisation is not held, only a current snapshot. Where a protocol publishes fees or revenue, this page shows the yield against that dated snapshot instead.
What is IBS's research score?
37.4/100 within DeFi, ranked 24 of 30 rated DeFi coins, on 50% evidence: 5.5 + 15.0 + 10.0 + 6.9 = 37.4. It is labelled “Illiquid · research only”. The score ranks research attention inside one theme, never portfolio action.
How much IBS history does this page show?
Five years of weekly closes where they exist, plus 20 complete calendar quarters of on-chain activity for the metrics IBS actually publishes. No protocol fee, revenue, TVL or user series is published for this token, so none is shown.